This research project is testing the safety, tolerability and efficacy (the effect of the drug on the body) of AKP-11 administered to participants with atopic dermatitis. You are invited to take part in the study, which will enrol participants with atopic dermatitis based on diagnosis by a suitably qualified “Investigator” or “study doctor”.
If you are eligible, you will receive daily ointment of the study medication, from Day 1 through up to Day 28. After screening, you wil attend the clinic a total of 6 times. The AKP-11 will be applied twice-daily for up to 28 days.
If you are interested and would like more information, please contact:
Stephanie Buchanan – Study Coordinator
Phone: 9623 9448
Email sbuchanan@skincancer.asn.au
Website: https://www.ctc.asn.au/trials/AD
Eligible participants in this clinical study will receive reimbursement for their time and travel. Bellberry Ethics Committee has approved this study.
